Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $59
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Yigal Nochomovitz maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $53 to $59.
Citigroup analyst Yigal Nochomovitz maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $53 to $59.